CALIBRATE: Encaleret vs Standard of Care in Autosomal Dominant Hypocalcemia Type 1

Phase 3, randomised, open-label trial in autosomal dominant hypocalcemia type 1 (ADH1) comparing Encaleret with Standard of Care (SoC) (2 arms). Primary endpoint: Number of Responders who Achieve Both Albumin-Corrected Blood Calcium (cCa) and 24-hour Urinary Calcium (UCa) Within the Target Range at 24 weeks. Started Jan 2023; status: active, not recruiting.